CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$219.49M, lower than 95% of all stocks globally
- PositionGross margin is -57.3%, lower than 95% of its Biotechnology peers (median 77.2%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
2.01BUSDvs all stocks (USD)
Revenue (TTM)
54.86MUSDvs all stocks (USD)
Beta
1.07xvs all stocks
52-Week Change
-23.83%vs all stocks
Market Capitalization
2.01BUSDvs all stocks (USD)
Enterprise Value
1.52BUSDvs all stocks (USD)
Forward P/E
-4.15xvs Biotechnology peers
Price to Sales (TTM)
36.56xvs Biotechnology peers
Price to Book (MRQ)
2.19xvs Biotechnology peers
Enterprise to Revenue
27.77xvs Biotechnology peers
Enterprise to EBITDA
-3.23xvs Biotechnology peers
Gross Margin
-57.35%vs Biotechnology peers
Operating Margin
-1759.69%vs Biotechnology peers
Return on Assets (TTM)
-27.33%vs Biotechnology peers
Return on Equity (TTM)
-56.58%vs Biotechnology peers
Revenue (TTM)
54.86MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1080USDUpdated Sep 28, 2026Quarterly Revenue Growth
-60.10%vs Biotechnology peers
Gross Profit (TTM)
-392.60MUSDvs all stocks (USD)
EBITDA (TTM)
-471.60MUSDvs all stocks (USD)
Net Income (TTM)
-518.88MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-61.77%vs Biotechnology peers
Operating Cash Flow (TTM)
-350.48MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-219.49MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
74.26MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
70.95MUSDFY2025 · Dec 31, 2025Gross Profit
3.30MUSDFY2025 · Dec 31, 2025Operating Income
-648.13MUSDvs all stocks (USD)
Pre-tax Income
-644.89MUSDFY2025 · Dec 31, 2025Income Tax Expense
-136.00KUSDFY2025 · Dec 31, 2025Net Income
-644.76MUSDFY2025 · Dec 31, 2025EBIT
-643.09MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-559.38MUSDFY2025 · Dec 31, 2025Research & Development
475.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
176.59MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-425.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Income
22.79MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.81MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.44USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.44USDFY2025 · Dec 31, 2025Basic Shares Outstanding
447.45MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
447.45MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-644.76MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-422.39MUSDFY2025 · Dec 31, 2025Free Cash Flow
-428.86MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
753.92MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-644.76MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
83.70MUSDFY2025 · Dec 31, 2025Stock-based Compensation
111.22MUSDFY2025 · Dec 31, 2025Other Non-cash Items
53.88MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
32.94MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.62MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-56.76MUSDFY2025 · Dec 31, 2025Capital Expenditures
-6.47MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.16MUSDFY2025 · Dec 31, 2025Net Acquisitions
-4.44MUSDFY2025 · Dec 31, 2025Purchase of Investments
-3.81MUSDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-14.71MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-8.43MUSDFY2025 · Dec 31, 2025Other Financing Charges
-3.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
517.44MUSDFY2025 · Dec 31, 2025Shares Outstanding
534.12MSharesUpdated Sep 28, 2026Float Shares
518.47MSharesUpdated Sep 28, 2026Shares Short
178.72MSharesUpdated Sep 28, 2026Short Ratio
11.32daysvs all stocks
Short % of Shares Outstanding
34.95%vs all stocks
% Held by Insiders
2.27%vs all stocks
% Held by Institutions
70.62%vs all stocks
Total Cash (MRQ)
545.68MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.02USDUpdated Sep 28, 2026Total Debt (MRQ)
66.64MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0728xvs Biotechnology peers
Current Ratio (MRQ)
5.03xvs Biotechnology peers
Book Value per Share (MRQ)
1.71USDUpdated Sep 28, 2026Total Assets
1.47BUSDvs all stocks (USD)
Total Current Assets
812.85MUSDFY2025 · Dec 31, 2025Total Liabilities
343.26MUSDFY2025 · Dec 31, 2025Total Non-current Assets
661.28MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
195.56MUSDFY2025 · Dec 31, 2025Total Current Liabilities
147.71MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
743.29MUSDFY2025 · Dec 31, 2025Accounts Payable
18.12MUSDFY2025 · Dec 31, 2025Short-term Debt
21.75MUSDFY2025 · Dec 31, 2025Deferred Revenue
37.60MUSDFY2025 · Dec 31, 2025Long-term Debt
56.21MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
2.08MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.08BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.13BUSDvs all stocks (USD)
52-Week Low
2.77USDUpdated Sep 28, 202652-Week High
7.18USDUpdated Sep 28, 202652-Week Change
-23.83%vs all stocks
Beta
1.07xvs all stocks
50-Day MA
3.32USDUpdated Sep 28, 2026200-Day MA
3.59USDUpdated Sep 28, 2026Avg 10-Day Volume
24.80MSharesUpdated Sep 28, 2026Avg 30-Day Volume
18.70MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.00USDUpdated Sep 28, 2026Other Income / Expense
-17.74MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -57.3%, lower than 95% of its Biotechnology peers (median 77.2%)Significant
Gross margin: -0.57Industry median: 0.77Industry P5: 0.18Peers compared: 193
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 36.56Revenue Growth YoY: -0.60
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 5.03Altman Z-Score: 0.69
Financial Health
Altman Z-Score 0.69: distress zoneCritical
Altman Z-Score: 0.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$219.49M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -219,493,744Global P5: -202,685,365.334
Market cap is $2.01B, above the global median of $1.18BNotable
Market cap (USD): 2,005,653,865Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Urogen Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mesoblast Limited
Tier 1ProductionApproval-Gated PipelineRule
Nuvation Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sk Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Galapagos NV
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inspire Medical Systems, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Clearwater Analytics Holdings Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Hunan Kylinsec Technology Co., Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Kneat.com Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC